Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 697

1.

Brief Report: SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-study).

Edelman MJ, Redman MW, Albain KS, McGary EC, Rafique NM, Petro D, Waqar SN, Minichiello K, Miao J, Papadimitrakopoulou VA, Kelly K, Gandara DR, Herbst RS.

J Thorac Oncol. 2019 Jul 11. pii: S1556-0864(19)30557-X. doi: 10.1016/j.jtho.2019.06.027. [Epub ahead of print]

PMID:
31302234
2.

Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.

Herbst RS, Arkenau HT, Santana-Davila R, Calvo E, Paz-Ares L, Cassier PA, Bendell J, Penel N, Krebs MG, Martin-Liberal J, Isambert N, Soriano A, Wermke M, Cultrera J, Gao L, Widau RC, Mi G, Jin J, Ferry D, Fuchs CS, Petrylak DP, Chau I.

Lancet Oncol. 2019 Jul 10. pii: S1470-2045(19)30458-9. doi: 10.1016/S1470-2045(19)30458-9. [Epub ahead of print]

PMID:
31301962
3.

Myasthenia Gravis: Pathogenic Effects of Autoantibodies on Neuromuscular Architecture.

Koneczny I, Herbst R.

Cells. 2019 Jul 2;8(7). pii: E671. doi: 10.3390/cells8070671. Review.

4.

Quantification of In Vivo Target Engagement Using Microfluidic Activity-Based Protein Profiling.

Reardon HT, Herbst RA, Henry CL, Herbst DM, Ngo N, Cisar JS, Weber OD, Niphakis MJ, O'Neill GP.

SLAS Technol. 2019 Jun 14:2472630319852303. doi: 10.1177/2472630319852303. [Epub ahead of print]

PMID:
31199699
5.

Brief Report: SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously-treated Patients with Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study).

Aggarwal C, Redman MW, Lara PN Jr, Borghaei H, Hoffman P, Bradley JD, Newman AJ 3rd, Feldman MJ, Minichiello K, Miao J, Mack PC, Papadimitrakopoulou VA, Herbst RS, Kelly K, Gandara DR.

J Thorac Oncol. 2019 Jun 10. pii: S1556-0864(19)30462-9. doi: 10.1016/j.jtho.2019.05.041. [Epub ahead of print]

PMID:
31195180
6.

USING THE ATA AND ACR TI-RADS SONOGRAPHIC CLASSIFICATIONS AS ADJUNCTIVE PREDICTORS OF MALIGNANCY FOR INDETERMINATE THYROID NODULES.

Ahmadi S, Herbst R, Oyekunle T, Jiang X', Strickland K, Roman S, Sosa JA.

Endocr Pract. 2019 Jun 6. doi: 10.4158/EP-2018-0559. [Epub ahead of print]

PMID:
31170369
7.

Brief Report: SWOG S1400B (NCT02785913), A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study).

Langer CJ, Redman MW, Wade JL 3rd, Aggarwal C, Bradley JD, Crawford J, Stella PJ, Knapp MH, Miao J, Minichiello K, Herbst RS, Kelly K, Gandara DR, Papadimitrakopoulou VA.

J Thorac Oncol. 2019 May 31. pii: S1556-0864(19)30414-9. doi: 10.1016/j.jtho.2019.05.029. [Epub ahead of print]

PMID:
31158500
8.

Treatment of Maternal Depression in Pediatric Primary Care.

Herbst RB, Ammerman RT, Perry SP, Zion CE, Rummel MK, McClure JM, Stark LJ.

Clin Pediatr (Phila). 2019 May 21:9922819850469. doi: 10.1177/0009922819850469. [Epub ahead of print] No abstract available.

PMID:
31113226
9.

EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small cell lung cancer.

Hastings K, Yu H, Wei W, Sanchez-Vega F, DeVeaux M, Choi J, Rizvi H, Lisberg A, Truini A, Lydon CA, Liu Z, Henick BS, Wurtz A, Cai G, Plodkowski AJ, Long NM, Halpenny DF, Killam J, Oliva I, Schultz N, Riely GJ, Arcila ME, Ladanyi M, Zelterman D, Herbst RS, Goldberg SB, Awad MM, Garon EB, Gettinger S, Hellmann MD, Politi K.

Ann Oncol. 2019 May 14. pii: mdz141. doi: 10.1093/annonc/mdz141. [Epub ahead of print]

PMID:
31086949
10.

Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis.

Datar I, Sanmamed MF, Wang J, Henick BS, Choi J, Badri T, Dong W, Mani N, Toki M, Mejías LD, Lozano MD, Perez-Gracia JL, Velcheti V, Hellmann MD, Gainor JF, McEachern K, Jenkins D, Syrigos K, Politi K, Gettinger S, Rimm DL, Herbst RS, Melero I, Chen L, Schalper KA.

Clin Cancer Res. 2019 May 3. doi: 10.1158/1078-0432.CCR-18-4142. [Epub ahead of print]

PMID:
31053602
11.

A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity.

Karnell JL, Albulescu M, Drabic S, Wang L, Moate R, Baca M, Oganesyan V, Gunsior M, Thisted T, Yan L, Li J, Xiong X, Eck SC, de Los Reyes M, Yusuf I, Streicher K, Müller-Ladner U, Howe D, Ettinger R, Herbst R, Drappa J.

Sci Transl Med. 2019 Apr 24;11(489). pii: eaar6584. doi: 10.1126/scitranslmed.aar6584.

PMID:
31019027
12.

Nurse-Led Telephone Follow-Up to Improve Parent Promotion of Healthy Behaviors in Young Children With Motivational Interviewing Techniques.

Schlottmann H, Broome M, Herbst R, Burkhardt MC, Mescher A.

J Pediatr Health Care. 2019 Mar 27. pii: S0891-5245(18)30561-3. doi: 10.1016/j.pedhc.2019.02.003. [Epub ahead of print]

PMID:
30926151
13.

Larotrectinib in NTRK-Rearranged Solid TumorsPublished as part of the Biochemistry series "Biochemistry to Bedside".

Wilson FH, Herbst RS.

Biochemistry. 2019 Mar 26;58(12):1555-1557. doi: 10.1021/acs.biochem.9b00126. Epub 2019 Mar 13. No abstract available.

PMID:
30865435
14.

Immune Checkpoint Inhibitor-Associated Pericarditis.

Altan M, Toki MI, Gettinger SN, Carvajal-Hausdorf DE, Zugazagoitia J, Sinard JH, Herbst RS, Rimm DL.

J Thorac Oncol. 2019 Jun;14(6):1102-1108. doi: 10.1016/j.jtho.2019.02.026. Epub 2019 Mar 7.

PMID:
30851443
15.

Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC).

Carvajal-Hausdorf D, Altan M, Velcheti V, Gettinger SN, Herbst RS, Rimm DL, Schalper KA.

J Immunother Cancer. 2019 Mar 8;7(1):65. doi: 10.1186/s40425-019-0540-1.

16.

Effective Implementation of Culturally Appropriate Tools in Addressing Overweight and Obesity in an Urban Underserved Early Childhood Population in Pediatric Primary Care.

Herbst RB, Khalsa AS, Schlottmann H, Kerrey MK, Glass K, Burkhardt MC.

Clin Pediatr (Phila). 2019 May;58(5):511-520. doi: 10.1177/0009922819832088. Epub 2019 Mar 6.

PMID:
30841719
17.

Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy.

Wang J, Sun J, Liu LN, Flies DB, Nie X, Toki M, Zhang J, Song C, Zarr M, Zhou X, Han X, Archer KA, O'Neill T, Herbst RS, Boto AN, Sanmamed MF, Langermann S, Rimm DL, Chen L.

Nat Med. 2019 Apr;25(4):656-666. doi: 10.1038/s41591-019-0374-x. Epub 2019 Mar 4.

PMID:
30833750
18.

The fork in the road: Waun Ki Hong, John Mendelsohn, and the reinvigoration of The University of Texas MD Anderson Cancer Center.

Khuri FR, Herbst RS.

Cancer. 2019 May 15;125(10):1593-1596. doi: 10.1002/cncr.32045. Epub 2019 Mar 2. No abstract available.

PMID:
30825386
19.

Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes.

Doroshow DB, Sanmamed MF, Hastings K, Politi K, Rimm DL, Chen L, Melero I, Schalper KA, Herbst RS.

Clin Cancer Res. 2019 Mar 1. doi: 10.1158/1078-0432.CCR-18-1538. [Epub ahead of print] Review.

PMID:
30824587
20.

Convergent Identification and Interrogation of Tumor-Intrinsic Factors that Modulate Cancer Immunity In Vivo.

Codina A, Renauer PA, Wang G, Chow RD, Park JJ, Ye H, Zhang K, Dong MB, Gassaway B, Ye L, Errami Y, Shen L, Chang A, Jain D, Herbst RS, Bosenberg M, Rinehart J, Fan R, Chen S.

Cell Syst. 2019 Feb 27;8(2):136-151.e7. doi: 10.1016/j.cels.2019.01.004. Epub 2019 Feb 20.

PMID:
30797773

Supplemental Content

Loading ...
Support Center